Search Results

BIOLASE, Inc., a global leader in dental lasers, announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company’s common stock from The Nasdaq Stock Market.

BIOLASE, Inc., the global leader in dental lasers, announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock, one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock.

BIOLASE, Inc. announced that it received notice from the Staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550.

BIOLASE, Inc. today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock.

BIOLASE, Inc. announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

BIOLASE, Inc. who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, reported its financial results for the quarter and full year.

BIOLASE, Inc., the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608.